The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

Marketing authorization for the first EU vaccine to protect adolescents against chikungunya has been expedited for its public ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

If granted, the marketing authorization of VIMKUNYA would be valid in all EU member states, as well as in Iceland, Liechtenstein, and Norway. Based on the positive CHMP opinion, Bavarian Nordic ...